Source: International Congress 2015 – New data on established treatments for COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Nicholas Clarke (Cambridge, United States of America), Spencer Danto, Grant Langdon, Negin Shojaee, Jared Christensen, Nick Clarke, Lisa Tan, Christelle Perros-Huguet. Systemic inhibition of p38 MAPK improves lung function and inflammatory markers in moderate-severe COPD. Eur Respir J 2015; 46: Suppl. 59, 1484

Member's Comments

No comment yet.

Related content which might interest you: AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Inhibition of p38 mitogen-activated protein kinase has no effect on macrophage phagocytosis of bacteria in patients with COPD Source: Annual Congress 2013 –Macrophages, mononuclear cells and viral infection Year: 2013 PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 Aerobic exercise reduces asthma phenotype by inhibition of JAK2, SOCS3 and STAT6 in airway epithelium and in peribronchial leukocytes Source: International Congress 2016 – Latest insights into functional capacity and muscle weakness in chronic lung diseases Year: 2016 Synergistic effects of p38 MAPK inhibition with a corticosteroid in alveolar macrophages from corticosteroid insensitive asthma patients Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 Identification of novel pathogenic mechanisms triggered by arginase activation in patients with COPD Source: International Congress 2016 – Airway response to infection Year: 2016 Enrichment of the Janus kinase (JAK) activation signature in severe asthma sputum: Correlation with IL-13 expression Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 Treatment with Syk inhibitors after establishment of disease phenotype in a chronic HDM model of allergic airways inflammation abolishes AHR and attenuates inflammatory mediator expression Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Activation of the β-catenin pathway by Wnt-1 treatment suppress inflammation in the mouse model of allergic airway disease Source: International Congress 2015 – Advances in asthma and allergy in animal models Year: 2015 The correlation between expression of selected inflammatory mediators in induced sputum and respiratory tests in asthma and COPD Source: International Congress 2015 – Systemic and airway biomarkers Year: 2015 Sputum cell mRNA transcripts demonstrate alteration of endothelin metabolism in severe asthma and COPD Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 The effect of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild to moderate asthma Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Egr-1 regulates muc5ac expression through activator protein-1 (AP-1) in chronic airway inflammation diseases Source: International Congress 2015 – Translational studies in airway cell biology Year: 2015 IL-17A is elevated in patients with COPD and contributes to airway remodeling by acting on fibroblasts Source: International Congress 2016 – What's new in biomarker analysis? Year: 2016 Features of systemic inflammation in patients with stable COPD Source: International Congress 2014 – COPD: points to ponder Year: 2014 Targeting the mTOR signaling pathway to inhibit lung cell senescence in chronic obstructive pulmonary disease (COPD) Source: ERS Lung Science Conference 2017 Year: 2017 rHuKGF optimistically attenuates MAPK/ERK mediated cell proliferation pathway in emphysematous lungs Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases Year: 2013 cPLA2alpha inhibitor ASB14780 suppresses airway MMP-9 production and improves respiratory function in cigarette-smoke induced model Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Expression of vascular remodeling markers in relation to bradykinin receptors in asthma and COPD Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 Role of IκB kinases (IKKs) α and β in severe asthma and COPD Source: Eur Respir J 2005; 26: Suppl. 49, 2s Year: 2005